Pinnacle 21 Enterpriseソフトウェアは、規制当局によるすべての試験申請データの審査を迅速化
プリンストン、ニュージャージー：2021年10月28日 バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a five-year contract with Pinnacle 21 for ongoing software and related services support for the agency’s DataFit program. The DataFit program assesses data quality and performs data validation for standards compliance of all electronic clinical and non-clinical trial study submission data. This agreement is similar to the contracts awarded to Pinnacle 21 in 2015 and 2011 by the FDA. Pinnacle 21 was acquired by Certara in October 2021.
“We are honored by the FDA’s continued support of our Pinnacle 21 Enterprise software and partnership,” said William F. Feehery, PhD., CEO of Certara. “We are dedicated to making the drug development and submission process more efficient and user-friendly for regulatory agencies and biopharmaceutical companies, helping to get crucial new therapies to patients sooner.”
The DataFit custom implementation of Pinnacle 21 Enterprise meets the FDA’s data fitness assessment needs. The Pinnacle 21 Enterprise software enables the FDA to perform large-scale data validation and data quality reporting. FDA reviewers can assess and understand the quality of incoming submission data at a summary level in hours instead of the days or weeks required in a manual review.
“Regulatory agencies are embracing change and innovation to streamline the submission process. As the compliance standards are not easy to navigate, our software helps to automate validation and identify issues,” said Max Kanevsky, chief technology officer of Certara’s Software business unit. “Furthermore, beginning last month, the FDA is enforcing the technical rejection criteria, which are applicable to submissions to the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.”
The contract includes the use of the Pinnacle 21 Enterprise software by the FDA to perform data validation for its DataFit program as well as Operations and Maintenance through IT professional services to the FDA.
Certara（サターラ）について
サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。
本件に関するお問合わせ先
Jieun W. Choe
jieun.choe@certara.com
報道機関の皆様：
赤津 笑美
emi.akatsu@certara.com
ariane.lovell@finnpartners.com
投資家の皆様：
David Deuchler
Gilmartin Group
ir@certara.com
